Featured Research

from universities, journals, and other organizations

Staph vaccine shows promise in Phase I

Date:
January 20, 2011
Source:
American Society for Microbiology
Summary:
A new experimental vaccine against Staphylococcus aureus has been shown to be well-tolerated, and to boost antibodies, according to new research.

A new experimental vaccine against Staphylococcus aureus has been shown to be well-tolerated, and to boost antibodies, according to a paper in the December, 2010 issue of the journal Clinical and Vaccine Immunology. The vaccine was developed by Merck.

In the study, investigators led by Clayton Harro of the Johns Hopkins Bloomberg School of Public Health, Baltimore, gave a single vaccination in one of three different doses, or placebo, to four groups of 31 healthy volunteers, each, who ranged in age from 18-55. All three doses stimulated a rise in antibodies, the two higher doses significantly more so than the lowest dose. Antibody levels reached high levels after about 14 days, and they remained at those levels after three months.

"Based on this and other studies, the vaccine is now being tested in people who are at high risk of getting infected by S. aureus to see if the resulting antibodies can protect them from disease," says Harro. The need for such a vaccine is critical. S. aureus is the leading cause of hospital-acquired infections. "Invasive S. aureus infections (blood stream, deep wound, prosthetic device) have high associated morbidity and mortality," says Harro -- in the US and Europe, 6 million people become infected annually, and 140,000 die. Multidrug-resistant S. aureus is an increasing problem.

Vaccine design has been a big challenge, says Harro. "S. aureus has a complicated structure, a vast array of strains, and an uncanny capacity to evade immune surveillance systems in our bodies." But these complexities may have been rendered largely moot when the researchers discovered a single protein on the bacterial surface that is common to most S. aureus strains. Modern antigen discovery techniques, not available until recently, enabled the protein's discovery.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Harro, R. Betts, W. Orenstein, E.-J. Kwak, H. E. Greenberg, M. T. Onorato, J. Hartzel, J. Lipka, M. J. DiNubile, N. Kartsonis. Safety and Immunogenicity of a Novel Staphylococcus aureus Vaccine: Results from the First Study of the Vaccine Dose Range in Humans. Clinical and Vaccine Immunology, 2010; 17 (12): 1868 DOI: 10.1128/CVI.00356-10

Cite This Page:

American Society for Microbiology. "Staph vaccine shows promise in Phase I." ScienceDaily. ScienceDaily, 20 January 2011. <www.sciencedaily.com/releases/2011/01/110119191422.htm>.
American Society for Microbiology. (2011, January 20). Staph vaccine shows promise in Phase I. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2011/01/110119191422.htm
American Society for Microbiology. "Staph vaccine shows promise in Phase I." ScienceDaily. www.sciencedaily.com/releases/2011/01/110119191422.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins